ADIAL PHARMACEUTICALS, INC. - FORM S-1/A - EX-4.15 - AMENDMENT NO. 2 TO SENIOR SECURED PROMISSORY NOTE DATED AS OF NOVEMBER 21, 2017 - November 22, 2017

Attached files

file filename
EX-4.17 - FORM OF COMMON STOCK PURCHASE WARRANT DATED NOVEMBER 20, 2017 BY AND AMONG ADIAL - ADIAL PHARMACEUTICALS, INC.fs12017a3_ex4-17adialpharma.htm
EX-23.1 - CONSENT OF FRIEDMAN LLP - ADIAL PHARMACEUTICALS, INC.fs12017a3_ex23-1adialpharma.htm
S-1/A - AMENDMENT NO. 3 TO FORM S-1 - ADIAL PHARMACEUTICALS, INC.fs12017a3_adialpharma.htm
EX-10.22 - FORM OF SECURITY AGREEMENT - ADIAL PHARMACEUTICALS, INC.fs12017a3_ex10-22adialpharma.htm
EX-10.21 - SECURITIES PURCHASE AGREEMENT DATED AS OF NOVEMBER 20, 2017 BY AND AMONG ADIAL P - ADIAL PHARMACEUTICALS, INC.fs12017a3_ex10-21adialpharma.htm
EX-5.1 - OPINION OF GRACIN & MARLOW, LLP - ADIAL PHARMACEUTICALS, INC.fs12017a3ex5-1_adialpharma.htm
EX-4.16 - FORM OF SECURED PROMISSORY NOTES DATED AS OF NOVEMBER 21, 2017 BY AND BETWEEN AD - ADIAL PHARMACEUTICALS, INC.fs12017a3_ex4-16adialpharma.htm
EX-4.2 - FORM OF REPRESENTATIVE'S WARRANT AGREEMENT - ADIAL PHARMACEUTICALS, INC.fs12017a3_ex4-2adialpharma.htm
EX-1.1 - FORM OF UNDERWRITING AGREEMENT - ADIAL PHARMACEUTICALS, INC.fs12017a3_ex1-1adialpharma.htm

Exhibit 4.15

 

AMENDMENT 2 TO SENIOR SECURED PROMISSORY NOTE

 

This AMENDMENT 2, dated November 21, 2017 (the “Amendment”), to that certain senior secured promissory note of ADial Pharmaceuticals, LLC, as predecessor-in-interest to Adial Pharmaceuticals, Inc. (the “Company”), in the original principal amount of $287,500.00, dated May 1, 2017, as amended, (the “Note”) held by FirstFire Global Opportunities Fund LLC (“Holder”) is entered into by and between the Company and Holder. Capitalized terms used herein and not defined shall have the meanings set forth in the Note.

 

WITNESSETH:

 

WHEREAS, the Maturity Date of the Note is December 4, 2017;

 

WHEREAS, the Company and Holder desire to extend the Maturity Date to February 5, 2018 upon the terms and conditions set forth herein;

 

 NOW, THEREFORE, in consideration of the premises, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree to amend the Note as follows:

 

1.The Maturity Date shall mean, and be extended to, February 5, 2018.
2.On the Maturity Date the Company shall pay to Holder, and the Holder will accept, the sum of $375,000 in full and complete satisfaction of the principal sum of the Note and all accrued and unpaid interest thereon.
3.The Note, as amended by this Amendment, contains the entire agreement between the parties hereto regarding the subject matter thereof, and there are no agreements, warranties or representations which are not set forth therein or herein. This Amendment may not be modified or amended except by an instrument in writing duly signed by or on behalf of the parties hereto.
4.This Amendment shall be governed by and construed and enforced in accordance with the local laws of the State of New York applicable to agreements made and to be performed entirely within the State, without regard to conflict of laws principles.
5.This Amendment may be executed simultaneously in any number of counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.

 

Adial Pharmaceuticals, Inc.

 

 

 

 

By:   /s/ William Stilley                                  

Name: William Stilley

Title: Chief Executive Officer

 

 

FirstFire Global Opportunities Fund LLC

 

By FirstFire Capital Management LLC, its manager

 

 

By:   /s/ Eli Fireman                                                   

Name: Eli Fireman

 

 

 

 

 

 

 

ADIAL PHARMACEUTICALS, INC. Reports